Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Healthcare Needs and Illness Experience in Children With Rare Genetic and Metabolic Diseases (TD/MPP_1)

16 de novembro de 2026 atualizado por: Fondazione IRCCS San Gerardo dei Tintori

This prospective observational study aims to describe and characterize the multidimensional care needs of children and adolescents aged 1 month to 18 years with rare genetic and metabolic diseases, with particular emphasis on the identification of pediatric palliative care needs.

The study seeks to answer the question of which clinical, physical, psychological, social, and care-related needs characterize this population, and to what extent these needs are associated with complex care requirements and potential eligibility for pediatric palliative care.

Additional objectives include assessing pain, sleep disturbances, psychological well-being, quality of life, physical and social functioning, medication-related adverse events, symptom interference with daily life, and caregiver burden. The study will also explore individual care needs and the transition from pediatric to adult healthcare services.

A subgroup of approximately 150 participants will undergo longitudinal assessments every three months for up to 12 months to describe changes in care needs over time and identify factors potentially associated with worsening clinical and care complexity. Furthermore, a qualitative substudy involving caregivers and adolescents will explore the lived experience of illness and the meaning attributed to the disease by children and their families through semi-structured interviews.

Overall, the study aims to provide a comprehensive understanding of the care needs and illness experience of children with rare genetic and metabolic diseases, supporting the early identification of complex needs and the development of more personalized, proactive, and family-centered care pathways.

Visão geral do estudo

Status

Ainda não está recrutando

Tipo de estudo

Observacional

Inscrição (Estimado)

800

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Italy
      • Monza, Italy, Itália, 20900
        • Fondazione IRCCS San Gerardo dei Tintori

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

1 mês a 18 anos (Filho, Adulto)

Aceita Voluntários Saudáveis

N/D

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Study participants will be consecutively recruited from the outpatient clinics of Metabolic Diseases and Clinical Genetics at Fondazione IRCCS San Gerardo dei Tintori, a tertiary referral hospital located in Monza, Italy. The study population will include patients attending these clinics for specialist assessment and follow-up. For the qualitative substudy, caregivers and eligible adolescent patients will be selected from the same clinical population.

Descrição

Inclusion Criteria:

  • Participants aged between 1 month and 18 years.
  • Diagnosis of a rare genetic or metabolic disease.
  • Written informed consent freely provided by the parents and/or legal guardians and obtained before study participation.

Exclusion Criteria:

  • Diagnosis of trisomy 21 (Down syndrome).
  • Unavailability of cultural mediators or language interpreters during the information and informed consent process, as well as during the assessment of patients or caregivers with limited or no understanding of the Italian language.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: OTHER
  • Perspectivas de Tempo: PROSPECTIVE

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
AccaPed Total Score for the Assessment of Complex Pediatric Palliative Care Needs
Prazo: At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.

The total score of the AccaPed scale will be used to assess complex pediatric palliative care needs. The assessment will be performed at study enrollment in all participants. In a subgroup of approximately 150 participants, the assessment will be repeated every three months for 12 months to describe changes in care needs over time.

At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Paediatric Palliative Care Needs
Prazo: At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.

The Paediatric Palliative Screening Scale (PaPaS) will be used to assess pediatric palliative care needs in participants aged 1 to 18 years. The assessment will be performed at study enrollment in all eligible participants. In a subgroup of approximately 150 participants, the assessment will be repeated every three months for 12 months to evaluate changes in palliative care needs over time.

At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.
Pain Intensity Assessment
Prazo: At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.

Pain intensity will be assessed using age- and cognitive status-appropriate validated tools: the Revised Face, Legs, Activity, Cry, Consolability scale (r-FLACC), the Face, Legs, Activity, Cry, Consolability scale (FLACC), the Wong-Baker FACES Pain Rating Scale, or the Numeric Rating Scale (NRS). The most appropriate instrument will be selected according to the participant's age and cognitive status. The assessment will be performed at study enrollment in all eligible participants and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.
Assessment of Nociceptive Pain Phenotype
Prazo: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants, where applicable.

The nociceptive pain phenotype will be characterized through the assessment of central and peripheral sensitization using simplified Quantitative Sensory Testing (QST), the identification of nociplastic pain according to the definition of the International Association for the Study of Pain (IASP), and the assessment of neuropathic pain using the PainDETECT Questionnaire (PD-Q). The assessment tools will be selected according to the participant's age and cognitive status. Assessments will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months, where applicable.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants, where applicable.
Sleep Disturbances Assessment
Prazo: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

Sleep disturbances will be assessed using the Sleep Disturbance Scale for Children (SDSC) in participants aged 6 months to 18 years. The questionnaire will be completed by the researcher or caregiver. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Psychological Well-being Assessment
Prazo: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

Psychological aspects will be assessed using the Revised Children's Anxiety and Depression Scale (RCADS) in participants aged 8 to 18 years. The questionnaire will be completed by the researcher, caregiver, or participant, as appropriate. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Pain Catastrophizing Assessment
Prazo: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

Pain catastrophizing will be assessed using the Pain Catastrophizing Scale for Children (PCS-C) in participants aged 8 to 18 years. The questionnaire will be completed by the participant. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Health-Related Quality of Life Assessment
Prazo: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

Health-related quality of life will be assessed using the Pediatric Quality of Life Inventory (PedsQL) in participants aged 2 to 18 years. The appropriate version will be selected according to age, with the possibility of using the parent-proxy form for participants unable to complete the questionnaire because of age or cognitive impairment. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Physical Function Assessment
Prazo: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

Physical function will be assessed using the Gross Motor Function Classification System (GMFCS) in participants aged 1 to 18 years and the Function Disability Inventory (FDI) in participants aged 8 to 18 years. The FDI parent-report version may be used when required for children with cognitive difficulties. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Social Function Assessment
Prazo: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

Social function will be assessed using the KIDSCREEN-27 in participants aged 8 to 18 years, using the self-report or parent-proxy version as appropriate. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Pharmacological Treatment, Perceived Benefit, and Adverse Events
Prazo: At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.

Pharmacological treatment will be characterized by recording the number and type of medications taken, the perceived benefit of treatment, and any reported medication-related adverse events. Treatment-related changes will also be assessed using the Patient Global Impression of Change (PGIC) in participants aged 8 to 18 years and the Observer Global Impression of Change (OGIC) parent-proxy form in participants with cognitive impairment. Assessments will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.
Symptom Interference with Daily Life
Prazo: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.

The impact of symptoms on daily life will be assessed using the Symptom Screening in Pediatrics Tool (SSPedi). The self-report version will be used in participants aged 8 to 18 years, while the parent-proxy version will be used in participants aged 2 to 18 years, according to the participant's ability to complete the questionnaire. Assessments will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Caregiver Burden Assessment
Prazo: At study enrollment for all participants with an eligible caregiver assessment; every three months for 12 months in a subgroup of approximately 150 participants.

Caregiver burden will be assessed using the Caregiver Burden Inventory (CBI), completed by the caregiver. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.

At study enrollment for all participants with an eligible caregiver assessment; every three months for 12 months in a subgroup of approximately 150 participants.
Transition to Adult Healthcare Services
Prazo: During the 36-month study period.

The transition to adult healthcare services will be assessed by recording the proportion of patients requiring transfer to adult care, the proportion of patients for whom the transfer process has been initiated by 17 years and 6 months of age, and the proportion of patients effectively transferred to adult healthcare services upon reaching 18 years of age.

During the 36-month study period.
Individual Nursing Care Needs Classified According to ICNP
Prazo: At baseline; repeated every three months for 12 months in a subgroup of approximately 150 participants

Individual care needs will be identified and classified using the International Classification for Nursing Practice (ICNP), a standardized terminology for describing and documenting nursing practice. The assessment will support the systematic description of participants' individual nursing care needs.

At baseline; repeated every three months for 12 months in a subgroup of approximately 150 participants
Illness Experience and Meaning Attributed to the Disease by Children and Families
Prazo: Until data saturation is achieved during the study period.

The illness experience and the meaning attributed to the disease by children and their families will be explored through semi-structured interviews involving a subgroup of caregivers and adolescent participants aged 12 years or older. Interviews will be conducted until data saturation is achieved. The qualitative data will be analyzed to identify relevant themes concerning illness experience and care.

Until data saturation is achieved during the study period.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de novembro de 2026

Conclusão Primária (Estimado)

1 de novembro de 2029

Conclusão do estudo (Estimado)

1 de novembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

9 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • TD/MPP_1
  • 7408 (Outro identificador: Comitato Etico Territoriale Lombardia 3 (Territorial Ethics Committee Lombardy 3))

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever